Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cannabis-based drugs for IBD?

Research to be published in Gastroenterology as reported by BBC News this week gives the first evidence that selective cannabis-derived treatments may be useful as future therapeutic strategies for Crohn's and ulcerative colitis.

News image

fiogf49gjkf04

Some extracts from cannabis, known as cannabinoids, closely resemble molecules that occur naturally in our body.

Patients with inflammatory bowel disease (IBD) may benefit from cannabis-based drugs.

Anecdotally, people with IBD who have been users of cannabis have reported that their symptoms get better when they use the drug.

Dr Karen Wright and colleagues from England examined gut samples from healthy people and IBD patients.

The investigators looked for the presence of 2 receptors, CB1 and CB2, known to react to natural cannabis-like compounds produced by the body.

IBD patients had more CB2 receptors, that react to cannabis-like compounds produced by the body
BBC News

CB1 and CB2 receptors switch immune responses on or off, and CB1 receptors also help to promote wound healing in the lining of the gut.

The investigative team found that both the patients and the healthy people had similar numbers of CB1 receptors in their gut.

However, the IBD patients had far greater numbers of CB2 receptors.

Dr Wright concludes, “This gives us the first evidence that very selective cannabis-derived treatments may be useful as future therapeutic strategies in the treatment of Crohn's and ulcerative colitis.”

“The psychoactive effects and the legal implications associated with herbal cannabis use made it unsuitable as a treatment.”

“However, it might be possible to make a synthetic cannabis-like drug that has all of the therapeutic benefits and none of the other actions of cannabis.”

"Targeting drug development to components of the in-built cannabinoid system could be the way forward.”

Cannabis-based medicines are already used for multiple sclerosis in some countries.

Dr John Zycheck, from the Peninsula Medical School in Plymouth, England, has been granted £2 million to study these drugs for multiple sclerosis.

Dr Zycheck also comments, "There is no reason why clinical studies could not be undertaken at a fairly early stage because we are already testing cannabinoids for a variety of different conditions.”

"Cannabinoids do have an effect on the gut by slowing gut transit, which we see in our patients with multiple sclerosis."

In addition, Dr George Kunos from the US National Institutes of Health said, “An alternative approach could involve testing compounds that amplify the action of the body's natural cannabinoids by blocking their normal destruction in the gut.”

“Animal studies suggest that it is compounds blocking the enzyme fatty acid amidohydrolase that do this.”

Researchers agree that more work is needed to check whether these drugs would reduce inflammation and to work out a dose that is strong enough but not toxic.

BBC 2005: Sunday, 31 July, 23:04 GMT
02 August 2005

Go to top of page Email this page Email this page to a colleague

 24 May 2018 
Precision medicine for tumors
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 23 May 2018 
High body mass index is and ulcerative colitis
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us